E
Embody
A standard of care for poor patient outcomes insides the tendon and ligament repair space
About Embody
Embody is a pioneering company in the field of regenerative sports medicine, focusing on the development of advanced medical products for orthopedic patients. Since its inception in 2014, Embody has been dedicated to restoring peak performance for individuals suffering from tendon and ligament injuries. The company operates in the healthcare and medical technology market, serving a diverse range of clients including recreational athletes, professional sports teams, and military personnel.
Embody's core business model revolves around the creation and commercialization of novel collagen-based bio fabrication techniques and products. These innovative solutions are designed to enhance the healing process and improve the standard of care for tendon and ligament injuries. By leveraging advanced manufacturing processes, Embody aims to address the significant unmet needs in the orthopedic market, particularly for the 70,000 Achilles surgeries performed annually and the high incidence of soft tissue injuries among U.S. armed forces.
The company generates revenue through the sale of its proprietary medical products to healthcare providers, sports organizations, and military institutions. Embody's technology not only aims to expedite recovery times but also seeks to reduce the long-term impact of injuries, thereby maximizing return to performance for athletes and service members alike.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2015
- Headquarters
- Norfolk, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 60.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Nanotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jan 2023 | $155M | — | Zimmer Biomet | ↗ |
| SERIES COther financing | Sep 2022 | $10M | $42M | Genesis Innovation Group | ↗ |
Growth signals
Latest recorded traffic for Embody is 1.9K monthly website visits, up 143.6% over the last three months. Embody's team declined 88.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
DARPA
Series A2 investors entered at this stage
Genesis Innovation Group
Horizon Technology Finance Corporation
Series B and later2 investors entered at this stage
757 Angels
CIT GAP Funds
Other known investors2 additional known investors
Zimmer Biomet
Canyon Angels
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Embody on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Embody’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.